<DOC>
	<DOCNO>NCT01836562</DOCNO>
	<brief_summary>This clinical trial single Arm , single centre check safety efficacy bone marrow derive autologous mono nuclear cell ( MNC ) ( 100 million per dose ) . Trial conduct 36 month .</brief_summary>
	<brief_title>A Clinical Trial Study Safety Efficacy Bone Marrow Derived Autologous Cells Treatment Autism</brief_title>
	<detailed_description>Autism developmental disorder appear first 3 year life , affect brain 's normal development social communication skill . Autism physical condition link abnormal biology chemistry brain . The exact cause abnormality remain unknown , Symptoms-Children autism typically difficulty : Pretend play , Social interaction , Verbal non-verbal communication . Some child autism appear normal age 1 2 suddenly `` regress '' lose language social skill previously gain . This call regressive type autism . People autism may : Be overly sensitive sight , hearing , touch , smell , taste .</detailed_description>
	<mesh_term>Autistic Disorder</mesh_term>
	<criteria>Patient suffer Autism . willingness undergo bone marrow derive autologous cell therapy . patient provide fully Informed consent form study . Ability willingness regular visit hospital follow protocol Procedures . Patients pre exist Current systemic disease lung , liver ( exception ; History uncomplicated Hepatitis A ) , gastrointestinal , Cardiac , Immunodeficiency , ( include HIV ) Or laboratory Investigation could cause neurological defect.History Life threaten Allergic immune mediate reaction .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Autism stem cell MNCs</keyword>
</DOC>